Scientia Advisors in the News

Boston Globe quotes Harry Glorikian in article on "Drug giant bids $18.5b for Genzyme"

Robert Weisman
August 31, 2010

In this article by Robert Weisman of The Boston Globe, Harry Glorikian, Scientia Advisors' Managing Partner, comments on the tactic of asking stock owners to tender their shares, while the company's management is opposed to a sale. "Genzyme's hand could be forced. A shareholder might say, 'I'll take the $69. We've had some production problems, and we don't know what's around the corner.' If enough shareholders think it's a good deal, they've essentially sold the company."

Read the full article at: The Boston Globe

This comment from Harry Glorikian was also used in FiercePharma's article "Genzyme snubs Sanofi, but investors might not"

SCIENTIA ADVISORS, LLC | info@scientiaadv.com

55 Cambridge Parkway, Suite 300E, Cambridge MA 02142 | Phone: 617-299-3000 | Fax: 617-812-0315